PIPELINE
InnoCure is developing highly differentiated molecules for the treatment of cancer and rare diseases.
We have created a balanced portfolio of traditionally undruggable targets.
| Modality | Program | Indication | Discovery | Lead Optimization | IND Enabling | Phase l |
|---|---|---|---|---|---|---|
| MILPROTAC (Bivalent Degrader) |
ICTP - 101 | NSCLC, GC, Multiple | ||||
| Bivalent Degrader (PROTAC) |
ICTP - 201 | NUT midline carcinoma | ||||
| ICTP - 301 | Advanced solid tumor | |||||
| ICTP - 401 | Pancreatic cancer | |||||
| Bivalent Degrader (AUPTAC) |
ICTP - 501 | Multiple |